Bongioanni, M R <br/><br/>
Systemic high-dose recombinant-alpha-2a-interferon therapy modulates lymphokine production in multiple sclerosis.  [electronic resource] 

 -  Journal of the neurological sciences  Nov 1996 
 - 91-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0022-510X 
<br/><br/><label>Standard No.: </label>10.1016/s0022-510x(96)00176-1  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies--blood<br/>Antigens, Surface--metabolism<br/>Antineoplastic Agents--administration & dosage<br/>Cells, Cultured--chemistry<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Female<br/>Histocompatibility Antigens Class II--metabolism<br/>Humans<br/>Immunoglobulin G--biosynthesis<br/>Immunophenotyping<br/>Interferon alpha-2<br/>Interferon-alpha--administration & dosage<br/>Lymphocytes--cytology<br/>Lymphokines--biosynthesis<br/>Macrophages--chemistry<br/>Male<br/>Multiple Sclerosis--drug therapy<br/>Neutralization Tests<br/>Pilot Projects<br/>Placebos<br/>Recombinant Proteins--administration & dosage<br/>beta 2-Microglobulin--metabolism